Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Net Cash Flow data on file, last reported at $3.8 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $3.8 million, up 199.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 112.5% YoY), and the FY2025 annual result was -$3.3 million, down 107.54% from the prior year.
• Net Cash Flow improved to $3.8 million in Q1 2026 per LXRX's latest filing, from -$15.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $76.3 million in Q2 2023 and troughed at -$81.2 million in Q3 2023.
• A 5-year average of $177882.4 and a median of -$2.6 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 3002.26% in 2023, then surged 2754.03% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $27.5 million in 2022, then sank by 95.1% to $1.3 million in 2023, then soared by 2279.91% to $32.1 million in 2024, then sank by 147.75% to -$15.3 million in 2025, then surged by 124.55% to $3.8 million in 2026.
• Business Quant data shows LXRX's Net Cash Flow at $3.8 million in Q1 2026, -$15.3 million in Q4 2025, and $28.3 million in Q3 2025.